571 related articles for article (PubMed ID: 29990843)
1. A molecular approach in drug development for Alzheimer's disease.
Agatonovic-Kustrin S; Kettle C; Morton DW
Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
[TBL] [Abstract][Full Text] [Related]
2. Multiple Ligands Targeting Cholinesterases and β-Amyloid: Synthesis, Biological Evaluation of Heterodimeric Compounds with Benzylamine Pharmacophore.
Szałaj N; Bajda M; Dudek K; Brus B; Gobec S; Malawska B
Arch Pharm (Weinheim); 2015 Aug; 348(8):556-63. PubMed ID: 26032855
[TBL] [Abstract][Full Text] [Related]
3. [Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands].
Yang WC; Sun Q; Yu NX; Zhu XL; Yang GF
Yao Xue Xue Bao; 2012 Mar; 47(3):313-21. PubMed ID: 22645754
[TBL] [Abstract][Full Text] [Related]
4. Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer's Disease.
Kaniakova M; Nepovimova E; Kleteckova L; Skrenkova K; Holubova K; Chrienova Z; Hepnarova V; Kucera T; Kobrlova T; Vales K; Korabecny J; Soukup O; Horak M
Curr Alzheimer Res; 2019; 16(9):821-833. PubMed ID: 30819076
[TBL] [Abstract][Full Text] [Related]
5. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology.
Uddin MS; Kabir MT; Rahman MM; Mathew B; Shah MA; Ashraf GM
J Pharm Pharmacol; 2020 Aug; 72(8):1001-1012. PubMed ID: 32149402
[TBL] [Abstract][Full Text] [Related]
6. Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT
Więckowska A; Kołaczkowski M; Bucki A; Godyń J; Marcinkowska M; Więckowski K; Zaręba P; Siwek A; Kazek G; Głuch-Lutwin M; Mierzejewski P; Bienkowski P; Sienkiewicz-Jarosz H; Knez D; Wichur T; Gobec S; Malawska B
Eur J Med Chem; 2016 Nov; 124():63-81. PubMed ID: 27560283
[TBL] [Abstract][Full Text] [Related]
7. Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.
Uddin MS; Al Mamun A; Kabir MT; Ashraf GM; Bin-Jumah MN; Abdel-Daim MM
Mol Neurobiol; 2021 Jan; 58(1):281-303. PubMed ID: 32935230
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Geerts H; Grossberg GT
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
[TBL] [Abstract][Full Text] [Related]
10. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease.
Pathak C; Kabra UD
Bioorg Chem; 2024 Mar; 144():107152. PubMed ID: 38290187
[TBL] [Abstract][Full Text] [Related]
12. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil.
Woodruff-Pak DS; Tobia MJ; Jiao X; Beck KD; Servatius RJ
Neuropsychopharmacology; 2007 Jun; 32(6):1284-94. PubMed ID: 17119537
[TBL] [Abstract][Full Text] [Related]
13. Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond.
Koola MM
Psychiatry Res; 2020 Nov; 293():113409. PubMed ID: 32829072
[TBL] [Abstract][Full Text] [Related]
14. Development of 3D-QSAR Model for Acetylcholinesterase Inhibitors Using a Combination of Fingerprint, Molecular Docking, and Structure-Based Pharmacophore Approaches.
Lee S; Barron MG
Toxicol Sci; 2015 Nov; 148(1):60-70. PubMed ID: 26202430
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
16. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
17. Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice.
Liu T; Xia Z; Zhang WW; Xu JR; Ge XX; Li J; Cui Y; Qiu ZB; Xu J; Xie Q; Wang H; Chen HZ
Pharmacol Biochem Behav; 2013 Mar; 104():138-43. PubMed ID: 23262302
[TBL] [Abstract][Full Text] [Related]
18. Computational approach to suggest a new multi-target-directed ligand as a potential medication for Alzheimer's disease.
Eslami M; Nezafat N; Negahdaripour M; Ghasemi Y
J Biomol Struct Dyn; 2019 Nov; 37(18):4825-4839. PubMed ID: 30689517
[TBL] [Abstract][Full Text] [Related]
19. What is the rationale for new treatment strategies in Alzheimer's disease?
Rogawski MA
CNS Spectr; 2004 Jul; 9(7 Suppl 5):6-12. PubMed ID: 15241294
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
Rosini M; Simoni E; Bartolini M; Cavalli A; Ceccarini L; Pascu N; McClymont DW; Tarozzi A; Bolognesi ML; Minarini A; Tumiatti V; Andrisano V; Mellor IR; Melchiorre C
J Med Chem; 2008 Aug; 51(15):4381-4. PubMed ID: 18605718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
